Topiramate
Product Images NDC 70934-149

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

70934 149 30 Master Bottle Label Approval Rev B 02 19

Topiramate Tablets USP 25mg label shows a package of 30 tablets from Denton Pharma, Inc. DBA Northwind Pharmaceuticals. The label includes NDC 70934-149, dosage storage instructions, and warnings to keep out of reach of children and store in the original container protected from moisture.*

FDA Label Image

Topi (8768070b 575a 48af 8b99 76ca6dcf2087 01)

Chemical structure of the active ingredient Topiramate. The diagram shows the molecular arrangement of atoms including oxygen, carbon, sulfur, nitrogen, and hydrogen in the Topiramate molecule, highlighting its chemical bonds and stereochemistry.*

FDA Label Image

Topi (8768070b 575a 48af 8b99 76ca6dcf2087 02)

A cumulative rate graph depicting time to an event, with the y-axis labeled 'Cumulative Rates for Time to' and the x-axis representing time units up to 450. Three stepped line plots with different patterns show cumulative rates increasing over time, and a p-value of 0.0002 is noted on the chart.*

FDA Label Image

Figure 2: Reduction In 4-week Migraine Headache Frequency(studies 10 And 11 For Adults And Adolescents) (8768070b 575a 48af 8b99 76ca6dcf2087 03)

Bar graph showing change from baseline to double-blind phase in average weekly migraine period rate comparing Placebo, TOPAMAX 50 mg/day, 100 mg/day, and 200 mg/day across two studies (Study 10 and Study 11). Decreasing trends in migraine rate are observed with increasing TOPAMAX doses, with statistical significance indicated at 100 mg/day and 200 mg/day doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.